Author: Site Editor Publish Time: 2026-07-29 Origin: Site
Loncom Pharma (Shandong Loncom Pharmaceutical Co., Ltd.) has announced that its independently developed Ertugliflozin Tablets (Approval No. H20262506) have received marketing approval in China. This achievement represents another significant milestone in Loncom Pharma’s specialty generic drug development pipeline and highlights the company’s advanced pharmaceutical R&D capabilities.
Ertugliflozin is an oral Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitor used for the treatment of type 2 diabetes mellitus.
As an important therapeutic class in metabolic disease management, SGLT-2 inhibitors have attracted global attention due to their clinical value in glucose control and their expanding role in diabetes treatment.
The successful approval of Ertugliflozin Tablets demonstrates Loncom Pharma’s expertise in complex generic drug development, including pharmaceutical research, formulation optimization, bioequivalence study management, regulatory submission, and commercial manufacturing.
Founded in 2012, Loncom Pharma is a pharmaceutical technology company specializing in API development, formulation development, pharmaceutical manufacturing, and drug commercialization services.
The company has established three core technology platforms:
API and formulation development platform
Pharmaceutical manufacturing platform
Bioequivalence (BE) study platform
Through its integrated pharmaceutical R&D system, Loncom Pharma provides full lifecycle solutions, including:
Active Pharmaceutical Ingredient (API) development and manufacturing
Generic drug formulation development
Bioequivalence (BE) study support
Regulatory submission assistance
Technology transfer (TT)
Commercial-scale pharmaceutical manufacturing
This integrated capability enables Loncom Pharma to support partners from early-stage pharmaceutical development through successful commercialization.
With more than two decades of experience in pharmaceutical R&D, Loncom Pharma has established long-term partnerships with more than 200 pharmaceutical companies, including:
Over 50 leading pharmaceutical companies in China
More than 60 publicly listed pharmaceutical companies
Currently, Loncom Pharma has:
310+ ongoing pharmaceutical development projects
213 drug approvals obtained in the past five years
The company continues to expand its pipeline in high-value therapeutic areas, including:
Metabolic diseases
Central nervous system (CNS) disorders
Chronic disease treatments
Specialty generic medicines
With integrated capabilities covering API, formulation development, BE studies, regulatory support, and manufacturing, Loncom Pharma is committed to providing reliable pharmaceutical solutions for global partners.
Through continuous investment in pharmaceutical innovation and manufacturing excellence, Loncom Pharma aims to accelerate the development and global availability of high-quality medicines.
Loncom Pharma welcomes partnerships with global pharmaceutical companies in generic drug development, API supply, formulation development, technology transfer, and pharmaceutical manufacturing.
Q1: What is Ertugliflozin Tablets developed by Loncom Pharma?
A: Ertugliflozin Tablets are SGLT-2 inhibitor generic medicines independently developed by Loncom Pharma for metabolic disease treatment.
Q2: What pharmaceutical capabilities does Loncom Pharma provide?
A: Loncom Pharma provides integrated API development, formulation development, BE studies, regulatory support, technology transfer, and commercial manufacturing services.
Q3: What makes Loncom Pharma a reliable pharmaceutical partner?
A: Loncom Pharma combines pharmaceutical R&D platforms, manufacturing capabilities, and regulatory expertise to support the complete drug development lifecycle.
